Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.
Current concerns about multiresistance and a diminishing antibiotic pipeline are mainly addressed to Gram-negative bacteria. The greatest fear within the Gram-positive arena is vancomycin-resistant Staphylococcus aureus. Its epidemiology and clinical presentation give cause for concern, but so far its impact has been strictly limited. While this may change, the loss of glycopeptides as a treatment option may not, in fact, be all bad news.